- Home
- ASA vs RLAY Comparison
ASA vs RLAY Comparison
Compare ASA & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASA
- RLAY
- Stock Information
- Founded
- ASA 1958
- RLAY 2015
- Country
- ASA United States
- RLAY United States
- Employees
- ASA N/A
- RLAY N/A
- Industry
- ASA Precious Metals
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASA Industrials
- RLAY Health Care
- Exchange
- ASA Nasdaq
- RLAY Nasdaq
- Market Cap
- ASA 697.1M
- RLAY 619.0M
- IPO Year
- ASA N/A
- RLAY 2020
- Fundamental
- Price
- ASA $40.72
- RLAY $4.12
- Analyst Decision
- ASA
- RLAY Strong Buy
- Analyst Count
- ASA 0
- RLAY 13
- Target Price
- ASA N/A
- RLAY $18.00
- AVG Volume (30 Days)
- ASA 152.0K
- RLAY 1.2M
- Earning Date
- ASA 09-23-2025
- RLAY 11-05-2025
- Dividend Yield
- ASA 0.15%
- RLAY N/A
- EPS Growth
- ASA 331.75
- RLAY N/A
- EPS
- ASA 14.01
- RLAY N/A
- Revenue
- ASA $3,923,667.00
- RLAY $8,355,000.00
- Revenue This Year
- ASA N/A
- RLAY $31.55
- Revenue Next Year
- ASA N/A
- RLAY N/A
- P/E Ratio
- ASA $2.87
- RLAY N/A
- Revenue Growth
- ASA 66.52
- RLAY N/A
- 52 Week Low
- ASA $18.80
- RLAY $1.78
- 52 Week High
- ASA $40.97
- RLAY $8.32
- Technical
- Relative Strength Index (RSI)
- ASA 74.61
- RLAY 64.78
- Support Level
- ASA $38.10
- RLAY $3.87
- Resistance Level
- ASA $40.97
- RLAY $4.26
- Average True Range (ATR)
- ASA 0.90
- RLAY 0.23
- MACD
- ASA 0.28
- RLAY 0.05
- Stochastic Oscillator
- ASA 95.89
- RLAY 83.19
About ASA ASA Gold and Precious Metals Limited
ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).